COMMUNIQUÉS West-GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for [...]
Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
05/02/2026
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2 [...]
In a Defining Election Year, MAPS Releases Policy Guidebook to Shape the Future of Psychedelic Reform
05/02/2026
New resource offers legislators, advocates, and communities a roadmap for creating safe, equitable, and evidence-based psychedelic policies WASHINGTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- With the United States in a [...]
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/02/2026
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
05/02/2026
HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the [...]
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
05/02/2026
Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. ( Nasdaq: HSCS; HSCSW ) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or [...]
Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption
05/02/2026
Participating at the Society of Interventional Oncology Conference Will Allow the Company to Share Practical Insights and Personal Experiences HINGHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. ( [...]
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026
05/02/2026
FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
05/02/2026
-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage disorders (LSDs) [...]
Chiesi Global Rare Diseases Reinforces Long-Term Commitment to the Rare Disease Community with Multiple Abstract Presentations at the 22nd Annual WORLDSymposium™
05/02/2026
-- Chiesi’s abstract presentations will focus on clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- These scientific contributions in lysosomal storage disorders (LSDs) [...]
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
05/02/2026
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc. , a biotech company harnessing [...]
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
05/02/2026
ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following [...]
Basic Jane Advances Science-Led Cannabinoid Platform Focused on Senior Care and Scalable Product Formats
05/02/2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Basic Jane, a consumer product–focused subsidiary of Verda Bio, today highlighted its evolution from a mission-driven CBD brand into a scalable, partner-ready cannabinoid [...]
Catheter Precision’s LockeT Suture Retention Device to be Featured in Live Cases at Scripps’ Structural Heart Intervention and Imaging 2026 Conference
05/02/2026
FORT MILL, S.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a pioneer in medical technology for the cardiac electrophysiology market, today announced that its LockeT suture [...]
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women’s Health
05/02/2026
Milestone reflects accelerating adoption of innovative, non-surgical treatment options for uterine conditions TORONTO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “ [...]
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
05/02/2026
SAN FRANCISCO and BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim Emerging Outlook: [...]
Polaryx Therapeutics Welcomes New Members of the Board of Directors
05/02/2026
PARAMUS, NJ, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics , Inc. (Nasdaq: PLYX ) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Alumis to Participate in Upcoming February Investor Conferences
05/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today [...]
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
05/02/2026
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 [...]

Pages